Clinical Trial Update: Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial to compare the relative bioavailability of first- versus second-generation formulations of HRS9531 tablets in adults with obesity, currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• HRS9531

Snippet

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Conditions: Overweight or Obesity | Phase 1 | Status: RECRUITING